Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation

BACKGROUND: Pharmacogenetic (PGx) testing for germline variants in the DPYD and UGT1A1 genes can be used to guide fluoropyrimidine and irinotecan dosing, respectively. Despite the known association between PGx variants and chemotherapy toxicity, preemptive testing prior to chemotherapy initiation is...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau-Min, Kelsey S., Varughese, Lisa A., Nelson, Maria N., Cambareri, Christine, Reddy, Nandi J., Oyer, Randall A., Teitelbaum, Ursina R., Tuteja, Sony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742388/
https://www.ncbi.nlm.nih.gov/pubmed/34996412
http://dx.doi.org/10.1186/s12885-022-09171-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742388/
https://www.ncbi.nlm.nih.gov/pubmed/34996412
http://dx.doi.org/10.1186/s12885-022-09171-6

Ejemplares similares